Next-Generation Sequencing Panel Analysis of Clinically Relevant Mutations in Circulating Cell-Free DNA from Patients with Gestational Trophoblastic Neoplasia: A Pilot Study

Table 1

Clinical characteristics of the 11 GTN patients.

Patients	Age	Antecedent pregnancy	Interval from index pregnancy (months)	Distant metastasis (number)	Maximum lesion diameter (cm)	Plasma HCG level (U/L)	Chemotherapy regimens^∗	Surgery^#	Pathologic results	Diagnosis	Time for β-HCG recovering to normal level (days)	cfDNA concentration (ng/μL)
P1	48	Mole	1	Lung (6)	3.0	33740	EMA‐CO	TLH	Invasive mole	GTN III:6	63	0.181
P2	52	Mole	1	Lung (6)	6.6	>272600	EMA‐CO	TLH and BSO	Invasive mole	GTN III:9	112	0.928
P3	40	Mole	>12	No	8.2	1622	EMA‐CO	Uterine wedge resection	Choriocarcinoma	GTN I:8	80	0.522
P4	25	Mole	4	No	3.0	4209	Actinomycin D	Uterine wedge resection	Choriocarcinoma	GTN I:3	63	0.477
P5	34	Mole	3	No	3.1	170672	EMA‐CO	No	None	GTN I:5	60	0.28
P6	26	Mole	1	Lung (1)	7.0	5036	Actinomycin D	No	None	GTN III:4	76	0.596
P7	25	Mole	1	Lung (7)	4.2	12730	EMA‐CO	No	None	GTN III:5	69	0.199
P8	24	Mole	1	Lung (2)	3.9	12498	EMA‐CO	No	None	GTN III:4	89	0.419
P9	43	Abortion	3	No	5.0	121750	EMA‐CO	TLH	Choriocarcinoma	GTN I:8	111	0.517
P10	30	Abortion	2	Lung (4)	4.2	18030	EMA‐CO	D&C	Choriocarcinoma	GTN III:5	83	0.211
P11	28	Mole	4	No	6.1	15957	EMA‐CO	Uterine wedge resection	Invasive mole	GTN I:5	49	0.403

^∗EMA‐CO: etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine. ^#TLH: total laparoscopic hysterectomy; BSO: bilateral salphingo-oophorectomy; D&C: dilatation and curettage.